FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Gallium 68 PNT 6555 (Primary) ; Lutetium 177 PNT 6555 (Primary)
Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Malignant melanoma; Mouth neoplasm; Nasopharyngeal cancer; Oesophageal cancer; Oropharyngeal cancer; Pancreatic cancer; Pharyngeal neoplasms; Skin cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Acronyms FRONTIER
Sponsors Eli Lilly and Company; POINT Biopharma

01 Nov 2024 Planned number of patients changed from 30 to 24.
01 Nov 2023 Status changed from recruiting to active, no longer recruiting.
06 Jun 2023 Trial design, presented at the 59th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com